May 5, 2023 | ||
Impacted: All lines of business FDA and ACIP/CDC have provided new guidance for COVID-19 vaccines On April 18, 2023 the Food and Drug Administration (FDA) issued several updates to Emergency Use Authorizations (EUAs) of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines. There are two parts to this announcement:
Following the FDA’s updates, the Advisory Committee on Immunization Practices (ACIP) and Centers for Disease Control and Prevention (CDC) also issued an update of the Interim Clinical Considerations for use of COVID-19 Vaccines on Saturday, April 22, 2023. In response to the FDA and ACIP/CDC announcements Prime has made the following changes to Prime Standard Commercial and Medicaid COVID-19 vaccine drug lists. Prime Standard (PS) COVID-19 vaccine drug list changes: Monovalent formulations:
Bivalent formulations:
Note: ACIP and CDC are still finalizing a recommendation for the immunocompromised population. Prime will continue to monitor and will adjust QLs if applicable. If you have additional questions, please reach out to your Prime Client Engagement representative. To access additional Prime client communications and resources, check out the Prime Client Portal. If you don't have access to the portal, contact your IT administrator to request access, just as you would to access any Prime application. |
||
|
Share this email | Is this email not displaying correctly? View it in your browser. |
|||||
Prime Therapeutics |
||||||
© Prime Therapeutics LLC | PrimeTherapeutics.com | Update email preferences | Contact us | ||||||